D J Betteridge

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint Status report of lipid-lowering trials in diabetes
    D J Betteridge
    Department of Medicine, University College, London, UK
    Curr Opin Lipidol 11:621-6. 2000
  2. ncbi request reprint An investigation into the mechanisms mediating plasma lipoprotein-potentiated beta-amyloid fibrillogenesis
    Lee Stanyer
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, The Middlesex Hospital, Mortimer Street, W1N 8AA, London, UK
    FEBS Lett 518:72-8. 2002
  3. ncbi request reprint Long-term risk reduction: who needs treatment?
    D John Betteridge
    Endocrinology and Metabolism, Department of Medicine, University College London Medical School, London, UK
    Diabetes Res Clin Pract 68:S15-22. 2005
  4. ncbi request reprint Statins and diabetes
    Rafael Carmena
    Endocrine Service, Hospital Clinico Universitario, University of Valencia, Avda Blasco Ibanez 15, 46010 Valencia, Spain
    Semin Vasc Med 4:321-32. 2004
  5. ncbi request reprint Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes
    D J Betteridge
    Department of Medicine, University College London, Sir Jules Thorn Institute, The Middlesex Hospital, 5th Floor, Mortimer Street, London, W1N 8AA, UK
    Diabetologia 48:2477-81. 2005
  6. doi request reprint Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels
    D John Betteridge
    Department of Diabetes and Endocrinology, University College Hospital, London, UK
    Nat Rev Endocrinol 9:76-8. 2013
  7. ncbi request reprint CHD and diabetes--target dyslipidaemia, reduce the risk
    D John Betteridge
    Department of Medicine, London Medical School, University College, Mortimer Street, London W1T 3AA, UK
    Diabetes Res Clin Pract 61:S1-2. 2003
  8. ncbi request reprint Lipid-lowering trials in diabetes
    D J Betteridge
    Department of Medicine, Royal Free and University College Medical School, The Middlesex Hospital, London, UK
    Curr Opin Lipidol 12:619-23. 2001
  9. doi request reprint PROactive: time for a critical appraisal
    D John Betteridge
    Department of Medicine, Royal Free and University College Medical School, University College Hospital, Third Floor, 250 Euston Road, London NW1 2PQ, UK
    Eur Heart J 29:969-83. 2008
  10. ncbi request reprint Effects of pioglitazone on lipid and lipoprotein metabolism
    D John Betteridge
    Department of Medicine, Royal Free and University College Medical School, University College Hospital, London, UK
    Diabetes Obes Metab 9:640-7. 2007

Collaborators

Detail Information

Publications60

  1. ncbi request reprint Status report of lipid-lowering trials in diabetes
    D J Betteridge
    Department of Medicine, University College, London, UK
    Curr Opin Lipidol 11:621-6. 2000
    ..In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described...
  2. ncbi request reprint An investigation into the mechanisms mediating plasma lipoprotein-potentiated beta-amyloid fibrillogenesis
    Lee Stanyer
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, The Middlesex Hospital, Mortimer Street, W1N 8AA, London, UK
    FEBS Lett 518:72-8. 2002
    ..These data indicate that the apoprotein components of plasma lipoproteins play a key role in promoting Abeta polymerisation, possibly via interactions with aldehydes...
  3. ncbi request reprint Long-term risk reduction: who needs treatment?
    D John Betteridge
    Endocrinology and Metabolism, Department of Medicine, University College London Medical School, London, UK
    Diabetes Res Clin Pract 68:S15-22. 2005
    ..However, with physicians estimating that approximately 50% of patients with type 2 diabetes do not achieve these goals, initiation of appropriate, effective and rapid-acting statin therapy is paramount in these high-risk patients...
  4. ncbi request reprint Statins and diabetes
    Rafael Carmena
    Endocrine Service, Hospital Clinico Universitario, University of Valencia, Avda Blasco Ibanez 15, 46010 Valencia, Spain
    Semin Vasc Med 4:321-32. 2004
    ....
  5. ncbi request reprint Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes
    D J Betteridge
    Department of Medicine, University College London, Sir Jules Thorn Institute, The Middlesex Hospital, 5th Floor, Mortimer Street, London, W1N 8AA, UK
    Diabetologia 48:2477-81. 2005
    ..The aim of this study was to determine the long-term effects of pioglitazone add-on to metformin or sulphonylurea on plasma lipids and lipoproteins...
  6. doi request reprint Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels
    D John Betteridge
    Department of Diabetes and Endocrinology, University College Hospital, London, UK
    Nat Rev Endocrinol 9:76-8. 2013
    ..Inhibition of PCSK9 is potentially very important to the clinician, and should enable more patients to achieve their LDL-cholesterol-level goal...
  7. ncbi request reprint CHD and diabetes--target dyslipidaemia, reduce the risk
    D John Betteridge
    Department of Medicine, London Medical School, University College, Mortimer Street, London W1T 3AA, UK
    Diabetes Res Clin Pract 61:S1-2. 2003
  8. ncbi request reprint Lipid-lowering trials in diabetes
    D J Betteridge
    Department of Medicine, Royal Free and University College Medical School, The Middlesex Hospital, London, UK
    Curr Opin Lipidol 12:619-23. 2001
    ..In this study fenofibrate therapy was associated with reduced progression of coronary atherosclerosis assessed by quantitative coronary angiography...
  9. doi request reprint PROactive: time for a critical appraisal
    D John Betteridge
    Department of Medicine, Royal Free and University College Medical School, University College Hospital, Third Floor, 250 Euston Road, London NW1 2PQ, UK
    Eur Heart J 29:969-83. 2008
    ..In this article, we consider all the results from PROactive presented to date and offer our own appraisal of how these findings shape the CV efficacy and safety profile of pioglitazone...
  10. ncbi request reprint Effects of pioglitazone on lipid and lipoprotein metabolism
    D John Betteridge
    Department of Medicine, Royal Free and University College Medical School, University College Hospital, London, UK
    Diabetes Obes Metab 9:640-7. 2007
    ....
  11. ncbi request reprint Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes
    D J Betteridge
    University College Hospital, London and Hope Hospital, Salford, UK
    Diabet Med 24:541-9. 2007
    ..To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus and triglycerides < or = 6.0 mmol/l...
  12. ncbi request reprint Targeting dyslipidemia--the key to CHD risk reduction in the diabetic population?
    D John Betteridge
    Endocrinology and Metabolism, Department of Medicine, University College London Medical School, London, UK
    Diabetes Res Clin Pract 68:S1-2. 2005
  13. ncbi request reprint Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus
    John Betteridge
    Department of Medicine, Royal Free and University College Medical School, Middlesex Hospital, London, United Kingdom
    Am J Med 118:10-5. 2005
    ..Based on this evidence, patients with type 2 diabetes may be candidates for statin therapy regardless of LDL cholesterol level and in the absence of a previous CV event...
  14. doi request reprint Lipid lowering in diabetes mellitus
    D John Betteridge
    Department of Medicine, Royal Free and University College London, London, UK
    Curr Opin Lipidol 19:579-84. 2008
    ..Residual risk persists despite statin therapy and additional approaches, particularly in relation to increasing HDL cholesterol will be discussed...
  15. ncbi request reprint Diabetic dyslipidaemia
    D J Betteridge
    Royal Free and University College of Medical School, University College London, UK
    Diabetes Obes Metab 2:S31-6. 2000
    ..In the author's view, when ongoing studies are complete it is likely that most patients with type 2 diabetes will be prescribed lipid-lowering drugs...
  16. ncbi request reprint Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care
    D J Betteridge
    Department of Medicine, Sir Jules Thorn Institute, The Middlesex Hospital, London, UK
    Int J Clin Pract 58:153-68. 2004
    ..These guidelines present evidence and recommendations for the treatment of numerous atherothrombotic indications depending on individual patient circumstances...
  17. doi request reprint Thiazolidinediones and fracture risk in patients with Type 2 diabetes
    D J Betteridge
    Department of Medicine, Royal Free and University College Medical School, London, UK
    Diabet Med 28:759-71. 2011
    ..The potential clinical implications of any association are also discussed...
  18. doi request reprint Lipid control in patients with diabetes mellitus
    D John Betteridge
    Department of Diabetes and Endocrinology, University College Hospital, 3rd Floor Central, 250 Euston Road, London NW1 2PQ, UK
    Nat Rev Cardiol 8:278-90. 2011
    ..Large CVD end point trials, which include many patients with diabetes, are underway to test the combination of a statin and niacin versus a statin alone...
  19. ncbi request reprint The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease
    S S Soedamah-Muthu
    Royal Free and University College London Medical School, London, UK
    Atherosclerosis 167:243-55. 2003
    ....
  20. ncbi request reprint Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
    M J Thomason
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Diabet Med 21:901-5. 2004
    ....
  21. ncbi request reprint Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)
    M Raikou
    LSE Health and Social Care, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK
    Diabetologia 50:733-40. 2007
    ..We estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovascular disease in patients with type 2 diabetes using data from the Collaborative Atorvastatin Diabetes Study (CARDS)...
  22. ncbi request reprint Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)
    G A Hitman
    Centre for Diabetes and Metabolic Medicine, Barts and The London Queen Mary s School of Medicine and Dentistry, University of London, London, UK
    Diabet Med 24:1313-21. 2007
    ..14 mmol/l, no history of macrovascular disease and randomized to atorvastatin 10 mg daily or placebo]...
  23. ncbi request reprint Measures of oxidative stress in heterozygous familial hypercholesterolaemia
    J Nourooz-Zadeh
    Division of Medicine, Department of Medicine, Royal Free and University College Medical School, The Middlesex Hospital, Mortimer Street, W1N 8AA, London, UK
    Atherosclerosis 156:435-41. 2001
    ..These data suggest that oxidative stress is increased in FH-patients and is particularly pronounced in those patients with vascular disease. It is possible that increased oxidative stress may precede the development of vascular disease...
  24. pmc Clinical and laboratory responses to niceritrol in the treatment of hypercholesterolaemia
    L D Curtis
    Department of Medicine, University College and Middlesex School of Medicine, London, UK
    Postgrad Med J 64:672-5. 1988
    ..Thus niceritrol has been found to be beneficial in the treatment of both familial and polygenic hypercholesterolaemia...
  25. ncbi request reprint Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Helen M Colhoun
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Lancet 364:685-96. 2004
    ..We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol...
  26. ncbi request reprint The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
    K Al Majali
    Royal Free and University College Medical School, Department of Medicine, 5th Floor Jules Thorn Institute, Middlesex Hospital, Mortimer St, London W1N 8AA, UK
    Diabetologia 49:527-37. 2006
    ..To this aim we studied fasting and postprandial lipaemia in type 2 diabetic patients before and after sensitisation to insulin with pioglitazone, compared with that observed in patients on an insulin-providing regime...
  27. ncbi request reprint Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes
    H M Colhoun
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Diabet Med 19:201-11. 2002
    ..This paper describes the design of a collaborative clinical trial between Diabetes UK, the NHS Research and Development Directorate and Pfizer UK, that addresses this question...
  28. ncbi request reprint Platelet aggregation may not be a prerequisite for collagen-stimulated platelet generation of nitric oxide
    C C Smith
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, Middlesex Hospital, Mortimer Street, London, UK
    Biochim Biophys Acta 1473:286-92. 1999
    ..Such a mechanism could operate in vivo to inhibit platelet aggregation which might otherwise be induced by low concentrations of circulating agonists...
  29. ncbi request reprint Lipid management: past, present, and future
    D J Betteridge
    Department of Medicine, Middlesex Hospital, London, UK
    Br J Clin Pract Suppl 77:1-10. 1996
    ..In the meantime the task of the clinician is to put into practice what is now known particularly about the secondary prevention of CHD to ensure that patients benefit from recent advances in knowledge...
  30. ncbi request reprint Platelet secretion of beta-amyloid is increased in hypercholesterolaemia
    C C Smith
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, Gower Street Campus, The Middlesex Hospital, Mortimer Street, W1N 8AA, London, UK
    Brain Res 896:161-4. 2001
    ..These data indicate that abnormal platelet Abeta release occurs in hypercholesterolaemia...
  31. ncbi request reprint Platelet noradrenaline and adrenaline efflux in hypercholesterolaemia: studies in platelet-rich plasma
    C T Smith
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, The Middlesex Hospital, London, UK
    Platelets 11:395-400. 2000
    ..02) and low-density lipoprotein (p<0.02). These data provide additional evidence for catecholaminergic abnormalities in hypercholesterolaemia...
  32. ncbi request reprint Soluble beta-amyloid (A beta) 40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed
    Christopher C T Smith
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Neurosci Lett 367:129-32. 2004
    ..By contrast, at higher concentrations A beta 40 may potentiate vasoconstriction via the generation of toxic A beta oligomers which act on the endothelium to reduce vasodilator output...
  33. ncbi request reprint Native and oxidized low-density lipoproteins modulate the vasoactive actions of soluble beta-amyloid peptides in rat aorta
    Christopher C T Smith
    The Hatter Cardiovascular Institute, University College London Hospital and Medical School, 67 Chenies Mews, London WC1E 6HX, UK
    Clin Sci (Lond) 113:427-34. 2007
    ..Mechanisms whereby a treatable condition, namely hypercholesterolaemia, might contribute to the development of the cerebrovascular component of AD are indicated...
  34. ncbi request reprint Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA st
    D John Betteridge
    Department of Medicine, University College London, London, United Kingdom
    Am J Cardiol 100:1245-8. 2007
    ..001 vs atorvastatin). In conclusion, CRP was effectively decreased in patients with type 2 diabetes receiving rosuvastatin or atorvastatin, whereas rosuvastatin decreased LDL cholesterol significantly more than atorvastatin...
  35. ncbi request reprint Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone
    Michael B Cooper
    Department of Medicine, University College and Royal Free School of Medicine, University College London, London, UK
    Clin Endocrinol (Oxf) 68:738-46. 2008
    ..The objective was to investigate fasting and postprandial release of insulin, proinsulin (PI) and 32-33 split proinsulin (SPI) before and after sensitization to insulin with pioglitazone compared to a group treated with glibenclamide...
  36. ncbi request reprint Evaluation of methods for the extraction of nitrite and nitrate in biological fluids employing high-performance anion-exchange liquid chromatography for their determination
    Christopher C T Smith
    Department of Medicine, Royal Free and University College Medical School, Gower Street Campus, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    J Chromatogr B Analyt Technol Biomed Life Sci 779:201-9. 2002
    ..Our procedure may be suitable for routine determination of NO(2)(-) and NO(3)(-) in various biological fluids, e.g., plasma...
  37. doi request reprint CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone
    D John Betteridge
    Department of Diabetes and Endocrinology, University College Hospital, London, UK
    Fundam Clin Pharmacol 23:675-9. 2009
    ..These findings strongly suggest that pioglitazone has an important place in the management of type 2 diabetes...
  38. ncbi request reprint Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?
    Jeffrey W Stephens
    Department of Diabetes and Endocrinology, UCL Hospitals, Mortimer Street, London, UK
    Eur J Cardiovasc Prev Rehabil 11:521-8. 2004
    ..Our aim was to examine their efficacy in a clinic-based population of diabetic patients...
  39. ncbi request reprint Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans
    Christopher C T Smith
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, The Middlesex Hospital, Mortimer Street, London WIN 8AA, UK
    Neurosci Lett 367:48-50. 2004
    ..These data are consistent with ageing, the primary risk factor for AD, but not hyperlipidaemia influencing circulating A beta 40 levels...
  40. ncbi request reprint PPARS, insulin resistance and type 2 diabetes
    F Kaplan
    Department of Medicine, Royal Free and University College Medical School, The Middlesex Hospital, London, UK
    J Cardiovasc Risk 8:211-7. 2001
    ..The future certainly looks exciting in this area...
  41. ncbi request reprint A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome?
    Rossitza P Naoumova
    MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK
    Lancet 359:2215-6. 2002
  42. ncbi request reprint Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes
    Karima Zitouni
    Department of Medicine, Royal Free and University College Medical School, Whittington Hospital, London, United Kingdom
    Kidney Int 67:1993-8. 2005
    ..Therefore, a pathway involving these factors could alter the vulnerability to renal disease and impact adversely on the rate of loss of renal function...
  43. ncbi request reprint Potentiation of beta-amyloid polymerisation by low-density lipoprotein enhances the peptide's vasoactivity
    Lee Stanyer
    Department of Medicine, Royal Free and University College Medical School, Sir Jules Thorn Institute, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Biochim Biophys Acta 1670:147-55. 2004
    ..Should plasma lipoproteins prove to play a role in cerebral A beta deposition their modification with statins or antioxidants may offer therapeutic benefit...
  44. ncbi request reprint The generation of the F(2)-isoprostane 8-epi-PGF(2alpha) by human platelets on collagen stimulation
    C C Smith
    Department of Medicine, Royal Freeand University College Medical School, Sir Jules Thorn Institute, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Platelets 10:253-6. 1999
    ..These data confirm a previous report that activated platelets release the F2-isoprostane 8-epi-PGF(2alpha), accompanying the release of a COX-derived product, 9alpha, 11alpha-PGF(2alpha)...
  45. ncbi request reprint A log-dose-response study of xipamide and its effect on metabolic parameters
    C W Owens
    Department of Clinical Pharmacology, University College, London, UK
    J Hypertens Suppl 7:S320-1. 1989
    ..28 to 2.32 mmol/l. Triglycerides, very-low-density lipoprotein cholesterol and plasma aldosterone increased at the maximum dose; the cholesterol ratio, however, was unchanged...
  46. ncbi request reprint The current management of diabetic dyslipidaemia
    D J Betteridge
    Department of Medicine, Sir Jules Thorn Institute, The Middlesex Hospital, London, UK
    Acta Diabetol 38:S15-9. 2001
    ..Results from these studies will likely add further support to the recommendations to use statins in the overall management of diabetic patients...
  47. ncbi request reprint Human cytomegalovirus seropositivity is associated with impaired vascular function
    Cairistine Grahame-Clarke
    Department of Epidemiology and Public Health, University College London, 5 University St, London, WC1E 6JJ, UK
    Circulation 108:678-83. 2003
    ....
  48. ncbi request reprint Exaggerated polymerisation of beta-amyloid 40 stimulated by plasma lipoproteins results in fibrillar Abeta preparations that are ineffective in promoting ADP-induced platelet aggregation
    Lee Stanyer
    Department of Medicine, Sir Jules Thorn Institute, Royal Free and University College Medical School, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Biochim Biophys Acta 1674:305-11. 2004
    ..We suggest that lipoproteins may interfere with the recognition of Abeta by appropriate platelet receptors and/or cause Abeta to assume an "overaggregated" biologically inert state...
  49. ncbi request reprint Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro
    N A Alarayyed
    Centre for Clinical Pharmacology, Department of Medicine, The Rayne Institute, Royal Free and University College Medical School, London, UK
    Platelets 13:267-71. 2002
    ..Thus, the effects of these drugs on PDGF release may be mediated through alternative cellular signalling mechanisms...
  50. pmc Effects of aspirin upon the flushing reaction induced by niceritrol
    R H Jay
    Department of Medicine, University College and Middlesex School of Medicine, Rayne Institute, London
    Br J Clin Pharmacol 29:120-2. 1990
    ..No significant difference was seen between the two dose levels. Prior dosing with aspirin may increase acceptability of niceritrol and hence improve compliance...
  51. ncbi request reprint Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress
    J Nourooz-Zadeh
    Department of Medicine, Royal Free and University College School of Medicine, London, UK
    Biochem Biophys Res Commun 330:731-6. 2005
    ..Simultaneous analysis of urinary 8-epi-PGF2alpha and its metabolites should provide unique tool in clinical trials exploring the role of oxidant injury in human disease...
  52. pmc Carnitine deficiency associated with long-term pivampicillin treatment: the effect of a replacement therapy regime
    S J Rose
    Brook General Hospital, London, UK
    Postgrad Med J 68:932-4. 1992
    ..In such cases a more aggressive carnitine replacement regime is indicated and pivampicillin should be avoided in patients requiring long-term antibiotic administration...
  53. ncbi request reprint Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance
    Patricia Iozzo
    Medical Research Council Clinical Sciences Centre, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London, UK
    Diabetes 51:3020-4. 2002
    ..We conclude that type 2 diabetes is specifically associated with myocardial IR that is independent of and nonadditive with angiographic CAD and proportional to skeletal muscle and whole-body IR...
  54. ncbi request reprint Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia
    Rossitza P Naoumova
    Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, London, UK
    Arterioscler Thromb Vasc Biol 23:2070-7. 2003
    ..The etiology of the lipid abnormalities (increased serum cholesterol and triglyceride or either lipid alone) is unknown...
  55. ncbi request reprint Plant sterols...from research to practice
    D John Betteridge
    Department of Medicine, University College Medical School, The Middlesex Hospital, Mortimer Street, W1T 3AA, London, UK
    Atheroscler Suppl 3:1-3. 2002
  56. doi request reprint The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)
    Connie B Newman
    Department of Medicine, New York University School of Medicine, VA Hospital, 423 East 23rd Street, Dept of Medicine 11093 South, New York, NY 10010, USA
    Diab Vasc Dis Res 5:177-83. 2008
    ..Overall, these data demonstrate that atorvastatin 10 mg was well tolerated in patients with type 2 diabetes during long-term treatment...
  57. ncbi request reprint Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)
    H Andrew W Neil
    Division of Public Health and Primary Health Care, University of Oxford, Old Road Campus, Headington, Oxford OX3 7LF, UK
    Diabetes Care 29:2378-84. 2006
    ..We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 65-75 years at randomization with 1,709 younger patients in the Collaborative Atorvastatin Diabetes Study (CARDS)...
  58. ncbi request reprint Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content
    E Louise Thomas
    The Robert Steiner MR Unit, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Atherosclerosis 195:e181-90. 2007
    ..72, p<0.01; r=.0.86, p<0.01, respectively). In patients with FCHL on conventional lipid-lowering therapy, the addition of pioglitazone acts favourably on several metabolic parameters...
  59. ncbi request reprint Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
    Robert Wilcox
    Department of Cardiovascular Medicine, Queen s Medical Centre, University Hospital, Nottingham, UK
    Stroke 38:865-73. 2007
    ..Diabetes is an important risk factor for stroke. We conducted analyses in patients who had entered the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) with a history of stroke or without stroke...
  60. ncbi request reprint Race-specific differences in antioxidant enzyme activity in patients with type 2 diabetes: a potential association with the risk of developing nephropathy
    Karima Zitouni
    Department of Cellular and Molecular Medicine, St George s Hospital NHS Trust, Thomas Addison Diabetes Centre, London SW17 ORE, UK
    Diabetes Care 28:1698-703. 2005
    ..We investigated whether alterations in antioxidant enzyme activity could account for this biochemical phenotype and examined the relationship with conventional markers of renal disease...